OMER
NasdaqOMEROS CORPORATION
Basic Materials · Pharmaceutical Preparations
Research view
Fundamentals · SEC EDGAR · FY 2020-12-31
Revenue & Earnings — fiscal year
🔒 price chart needs market-data feed$41.6M
2016
$64.8M
2017
$29.9M
2018
$111.8M
2019
$73.8M
2020
Snapshot
SEC EDGAR · FY 2020-12-31Revenue$73.8M
Net Income$-138.1M
Gross Profit—
Oper Income$-122.8M
EPS (dil)$-0.05
Rev/sh$1.02
FCF/sh$-1.60
Book/sh$-1.67
Gross M—
Oper M-166.4%
Profit M-187.0%
FCF M-157.4%
ROE114.3%
ROA-76.3%
ROIC-114.1%
R&D/Rev110.1%
Rev Y/Y-34.0%
Rev 3Y CAGR4.4%
EPS Y/Y98.1%
EPS 3Y CAGR—
FCF 3Y CAGR—
Payout—
Div/sh—
Shs Chg Y/Y+0.6%
Current Ratio4.12
Quick Ratio4.08
Debt/Eq-1.98
Int Coverage—
Net Debt$228.3M
Total Debt$238.8M
Cash & Eq$10.5M
Total Assets$181.0M
Oper CF$-116.1M
Capex$65,000
Free CF$-116.2M
Buybacks$0
Equity$-120.8M
Liabilities—
Shs Outstand0.07B
SectorBasic Materials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $41.6M | $64.8M | $29.9M | $111.8M | $73.8M |
| Gross Profit | — | — | — | — | — |
| Operating Income | $-54.3M | $-43.9M | $-112.2M | $-146.0M | $-156.9M |
| Net Income | $-66.7M | $-53.5M | $-126.8M | $-84.5M | $-138.1M |
| Diluted EPS | $-1.65 | $-1.17 | $-2.61 | $-1.71 | $-2.41 |
| Operating Cash Flow | $-51.5M | $-36.2M | $-103.7M | $-60.1M | $-100.1M |
| Free Cash Flow | $-51.6M | $-36.6M | $-104.3M | $-60.4M | $-100.4M |
COMMUNITY · $OMER0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.